Document Detail


Monoclonal antibodies in oncology therapeutics: present and future indications.
MedLine Citation:
PMID:  23286740     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Over the last decade, the field of oncology has undergone revolutionary changes. One of the major reasons contributing to this change is the improvement in our understanding of the biology of cancer. Recognition of novel targets on the cancer cell has enabled development of tools to attack those targets. Monoclonal antibodies represent such a therapy that has rapidly been adapted in almost all major cancer subtypes.
AREAS COVERED: This review intends to give a comprehensive overview of monoclonal antibodies, including mechanism of action, the currently approved agents and future targets. The authors reviewed published data as well as information from the ongoing clinical trials.
EXPERT OPINION: Monoclonal antibodies represent a major new advance in oncology therapy but there remains significant room for improvement.
Authors:
Divaya Bhutani; Ulka N Vaishampayan
Publication Detail:
Type:  Journal Article; Review     Date:  2013-01-04
Journal Detail:
Title:  Expert opinion on biological therapy     Volume:  13     ISSN:  1744-7682     ISO Abbreviation:  Expert Opin Biol Ther     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-10     Completed Date:  2013-06-19     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101125414     Medline TA:  Expert Opin Biol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  269-82     Citation Subset:  IM    
Affiliation:
Wayne State University, Barbara Ann Karmanos Cancer Institute, Department of Oncology, Department of Medicine, 4 Hudson Webber Cancer Research Center, 4100 John R, Detroit, MI 48201, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / immunology,  pharmacology,  therapeutic use*
Antibody-Dependent Cell Cytotoxicity / drug effects
Complement Activation / drug effects
Humans
Neoplasms / drug therapy*
Signal Transduction / drug effects
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Retrospective evaluation of doxorubicin-piroxicam combination for the treatment of transitional cell...
Next Document:  The influence of anatase-rutile mixed phase and ZnO blocking layer on dye-sensitized solar cells bas...